Hk Pharma

Hk Tumescent Pharma Corporation

Paytra Alan Klein

Jeffrey Alan Klein

Bram Alan Klein

A tumescent composition including a cannabinoid dissolved in a tumescent solution, wherein the tumescent solution includes a local anesthetic; a vasoconstrictor; and a pharmaceutically acceptable carrier, wherein a tumescent concentration of the cannabinoid is 1-2000 μg/kg and is simultaneously: below a threshold for local, subcutaneous tissue toxicity, above a threshold for positive local therapeutic effect, and above a concentration safely achievable by intravenous (IV), intramuscular (IM) or oral (PO) delivery. Also disclosed are methods of subcutaneous delivery of a cannabinoid to a subject including administering to the subject the tumescent composition.

Tumescent infiltration drug delivery of cannabinoids

A tumescent composition comprising a biologic drug in a tumescent solution, wherein a tumescent concentration of the biologic drug is simultaneously below a threshold for local, subcutaneous tissue toxicity, above a threshold for positive local therapeutic effect, and above a concentration safely achievable by intravenous (IV), intramuscular (IM) or oral (PO) delivery; and the tumescent solution comprises a vasoconstrictor; a pharmaceutically acceptable carrier; and optionally a local anesthetic.

Tumescent infiltration drug delivery of high subcutaneous drug concentrations with prolonged local and systemic effects and minimal local or systemic toxicity

A tumescent composition comprising a chemotherapy agent in a tumescent solution, wherein a tumescent concentration of the chemotherapy agent is simultaneously below a threshold for local, subcutaneous tissue toxicity, above a threshold for positive local therapeutic effect, and above a concentration safely achievable by intravenous (IV), intramuscular (IM) or oral (PO) delivery; and the tumescent solution comprises a vasoconstrictor; a pharmaceutically acceptable carrier; and optionally a local anesthetic.

A tumescent composition comprising a drug or a therapeutic agent in a tumescent solution, wherein a tumescent concentration of the drug or therapeutic agent is simultaneously below a threshold for local, subcutaneous tissue toxicity, above a threshold for positive local therapeutic effect, and above a concentration safely achievable by intravenous (IV), intramuscular (IM) or oral (PO) delivery; and the tumescent solution comprises a vasoconstrictor; a pharmaceutically acceptable carrier; and optionally a local anesthetic, wherein the tumescent solution does not comprise an antibiotic.

A tumescent composition including a cannabinoid dissolved in a tumescent solution, wherein the tumescent solution includes a local anesthetic; a vasoconstrictor; and a pharmaceutically acceptable carrier, wherein a tumescent concentration of the cannabinoid is 1-2000 &#x3bc;g/kg and is simultaneously: below a threshold for local, subcutaneous tissue toxicity, above a threshold for positive local therapeutic effect, and above a concentration safely achievable by intravenous (IV), intramuscular (IM) or oral (PO) delivery. Also disclosed are methods of subcutaneous delivery of a cannabinoid to a subject including administering to the subject the tumescent composition.

A tumescent contravenom solution including: (a) a vasoconstrictor, (b) a physiological crystalloid solution, and (c) optionally a contravenom agent that neutralizes tissue toxic enzymes present in a venom and/or a drug that impairs or paralyzes lymphatic smooth muscle function and impairs lymphatic transport of venom. Also described are methods of treating an envenomation in a subject, and a kit for performing the method of treating an envenomation.

Tumescent contravenom drug delivery

Disclosed are methods of subcutaneous delivery of a drug or a therapeutic agent to a subject comprising administering to said subject a tumescent composition comprising: (a) the drug or the therapeutic agent, wherein a tumescent concentration of the drug is simultaneously: 1) below a threshold for local, subcutaneous tissue toxicity, 2) above a threshold for positive local therapeutic effect, and 3) above a concentration achievable by intravenous (IV), intramuscular (IM) or oral (PO) delivery; (b) a vasoconstrictor; and (c) a pharmaceutically acceptable carrier. Some embodiments relate to a method of treating or preventing sepsis or Systemic Inflammatory Response Syndrome (SIRS) in a subject. Some embodiments relate to a tumescent solution for treating a localized viral infection, e.g., varicella-zoster (shingles), the tumescent solution comprising an antiviral agent.

Growing community of inventors

Newport Beach, CA, United States of America

Paytra Alan Klein